Zerigo Health

What Zerigo Health does

Zerigo Health is a San Diego-based, venture-backed private medical device and digital health company that develops and markets the first FDA-cleared portable narrowband UVB (NB-UVB) phototherapy system for at-home treatment of chronic skin conditions, including psoriasis, eczema, vitiligo, seborrheic dermatitis, and leukoderma across all Fitzpatrick skin types (I-VI). The platform pairs the handheld phototherapy device via Bluetooth to a companion iOS and Android mobile app that uses machine-learning to personalize dosing according to American Academy of Dermatology (AAD2) protocols, with cloud-based prescription control enforcing physician-prescribed regimens, photo-based progress tracking, and remote monitoring by dedicated Care Guides. The company also offers Virtual Visits for remote diagnosis and prescription.

The business operates a B2B2C model in which health plans and self-insured employers contract for the Zerigo Skin Health Program as a covered benefit with a 30-day implementation timeline, supplemented by direct-to-consumer acquisition through physician prescriptions and the company's own website enrollment flow. Channel partners include benefits consultants, PBMs, and distribution networks, with a 2022 strategic partnership with Artemis Health embedding Zerigo into payer and employer benefits-analytics workflows. Revenue is generated through device provision covered by employer health plans, insurance reimbursement under Medicare DMEPOS supplier standards, and multi-year contracts with risk-bearing buyers targeting the specialty-drug cost category for chronic skin conditions.

The company was founded in 2014 (FDA clearance of the device followed in May 2017), has raised approximately $67 million in cumulative outside capital across seed, Series A, and a $43 million Series B in October 2021, and operates with 11-50 employees from its headquarters in San Diego, California, serving U.S. patients only. Recent strategic activity through 2022-2024 has centered on expanding clinical indications (eczema), launching the Zerigo 2.0 platform, building payer-facing analytics partnerships, and refreshing the executive bench with CEO Lisa Rometty and a CGO/CPO/CMO/CFO suite drawn from CVS Health, Optum Rx, UnitedHealthcare, Express Scripts, and Amazon Health Services.

Name

Zerigo Health

Legal name

Zerigo Health, Inc.

Website

https://zerigohealth.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Zerigo Health is a San Diego-based private medical device company that markets the first FDA-cleared portable narrowband UVB phototherapy system, paired with a machine-learning mobile app and Care Guide support, for at-home treatment of psoriasis, eczema, and vitiligo, sold primarily to U.S. health plans, self-insured employers, and individual patients via prescription.

Ownership category

akta.pro rank

Product category

Connected home phototherapy for chronic skin conditions

NAICS

Hair, Nail, and Skin Care Services (81211)

SIC

Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Psoriasis & Eczema Specialty Care (HLAKACAL)

akta.pro secondary industries

Pigmentary Disorders (Vitiligo/Melasma) (HLAKACAM), Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning) (CRABAKAI)

Keywords

• Home phototherapy devices
• Chronic skin treatment
• Connected UVB therapy
• Digital dermatology platform
• FDA-cleared medical device

Headquarters

HQ city

La Jolla

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Device Sales / Insurance Reimbursement: Zerigo Health offers its FDA-cleared phototherapy device which may be covered through employer health plans at no cost to members, or reimbursed through insurance depending on diagnosis, medical history, and individual coverage policies. The device requires a physician prescription.
2. B2B Health Plan and Employer Contracts: Zerigo Health generates revenue through partnerships with health plans and self-insured employers who offer the Zerigo Solution as a benefit to their members/employees, targeting reduction in specialty drug costs for chronic skin conditions.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Zerigo Health sells the Zerigo Skin Health Program, an FDA-cleared at-home connected phototherapy system combining a handheld narrowband UVB device, a Bluetooth-paired mobile app that uses machine-learning to personalize dosing and track progress, and dedicated Care Guide support plus Virtual Visits with licensed prescribers. The program treats chronic skin conditions including psoriasis, eczema/atopic dermatitis, vitiligo, seborrheic dermatitis, and leukoderma on all Fitzpatrick skin types I–VI, and is delivered to members through health plan and self-insured employer benefit contracts or direct physician prescription.

Product overview

Zerigo Health offers the Zerigo Skin Health Program, a unified digital health platform that combines three core components: (1) the Zerigo Phototherapy Device — an FDA-cleared handheld NB-UVB phototherapy device that patients use at home or on the go, (2) the Zerigo Mobile App — which connects to the device via Bluetooth, uses machine-learning to personalize treatment dosing, and enables progress tracking through photo uploads, and (3) Zerigo Care Guides — dedicated support staff who provide coaching and technical assistance throughout the treatment journey. The platform also integrates Virtual Visits with licensed providers for remote diagnosis and prescription. Treatment protocols follow American Academy of Dermatology guidelines, with dosing controlled automatically by the device based on the patient's prescribed Fitzpatrick skin type. The system targets patients with psoriasis, atopic dermatitis (eczema), vitiligo, seborrheic dermatitis, and leukoderma across all skin types (I–VI).

Differentiator

Problem solved

Functional benefit

Products and services

• Zerigo Skin Health Program Comprehensive at-home phototherapy program combining the FDA-cleared handheld NB-UVB device, the Zerigo Mobile App with machine-learning personalization, dedicated Care Guide support, and Virtual Visits with licensed providers, designed for individuals with chronic skin conditions including psoriasis, eczema, vitiligo, seborrheic dermatitis, and leukoderma.
• Zerigo Phototherapy Device The first FDA-cleared portable narrowband UVB phototherapy handheld device that delivers clinical-grade light therapy in the user's home or on the go and pairs with the Zerigo Mobile App via Bluetooth to enforce physician-prescribed dosing protocols.
• Zerigo Mobile App Companion iOS and Android application that pairs with the Zerigo Phototherapy Device via Bluetooth, uses machine-learning to personalize treatment plans, tracks progress through photo uploads, sends treatment reminders, and connects patients to their Care Guides and prescribing physicians.
• Zerigo Care Guides Dedicated support team of RNs, MAs, and certified health and wellness coaches who onboard patients, drive treatment adherence, provide technical support, and coordinate with prescribing physicians throughout the treatment journey.
• Virtual Visits Access to licensed healthcare providers who can remotely diagnose chronic skin conditions and prescribe the Zerigo device, enabling patients to begin treatment without requiring in-person clinic visits.
• Zerigo 2.0 Ecosystem Updated version of the Zerigo platform with integrated guideline-recommended NB-UVB phototherapy dosing protocols that shorten in-home treatment time for psoriasis and eczema patients by half compared with prior protocols.
• Zerigo Eczema Solution Indication-specific extension of the Zerigo platform with integrated, guideline-recommended phototherapy dosing protocols for atopic dermatitis (eczema), complementing the existing psoriasis and vitiligo treatments.

Quantifiable outcome

• 73% treatment adherence rate among engaged Zerigo members
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

One partnership is on record.

• Artemis HealthcoreStrategic or Co-development Partner · 7 September 2022Partnership to help employers and health plans evaluate and manage rising specialty drug costs for chronic autoimmune skin conditions. Artemis clients gain access to Console analytics to measure Zerigo's impact on outcomes, quality of life, and costs. Clients can add Zerigo to benefits through existing Artemis agreements.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Daavlin: Manufacturer of phototherapy equipment (full-body and targeted NB-UVB/UVA systems) for dermatology clinics and home use. Most directly comparable to Zerigo as a NB-UVB phototherapy device maker; differences are channel (clinic/office-led vs. Zerigo's at-home, connected model) and integration with software/ML dosing.
• National Biological Corporation: Long-established US manufacturer of phototherapy cabinets and home phototherapy units for psoriasis and vitiligo. Competes in the same NB-UVB modality, though primarily through clinic-channel and capital equipment sales rather than Zerigo's connected, app-driven at-home model.
• Sensus Healthcare: Public dermatology device company offering superficial radiation therapy (SRT) and aesthetic laser systems used by dermatologists. A direct device-vendor peer in the dermatology treatment-device category, with overlap on regulatory pathway (FDA-cleared) and clinical buyer (dermatology practices).

Broad incumbents

• Hims & Hers Health: Large direct-to-consumer telehealth platform offering prescription treatments for skin, hair, sexual health, and mental health. Comparable as a DTC, employer-/payer-aware digital health brand in dermatology, but competes more with topical/oral therapies than with at-home phototherapy specifically.
• Ro: Direct-to-consumer telehealth company operating the Roman dermatology vertical with prescription topical and oral treatments for skin conditions. Overlaps with Zerigo on the dermatology DTC/online prescribing funnel and on the chronic skin condition patient, but is treatment-modality-adjacent rather than a device peer.
• Livongo (Teladoc Health): Chronic-condition digital health platform founded by Glen Tullman, now part of Teladoc Health. Closely comparable business model (connected device + coaching + data, B2B payer contracting) and serves as the strategic reference point for Zerigo's executive playbook, even though dermatology was not Livongo's focus.
• AbbVie (Skyrizi): Pharmaceutical incumbent whose Skyrizi (risankizumab) is a leading IL-23 biologic for psoriasis and a direct therapeutic alternative to NB-UVB phototherapy. Represents the largest competitive threat to Zerigo on the payer formulary side, given Skyrizi's share of dermatology specialty drug spend.
• Novartis (Cosentyx): Pharmaceutical incumbent marketing Cosentyx (secukinumab), a leading IL-17 biologic for psoriasis, psoriatic arthritis, and related conditions. Competes with Zerigo for the same patients and payer dollars, but via systemic drug therapy rather than at-home phototherapy.

Emerging players

• Omada Health: Digital chronic-condition management company selling to health plans and employers (diabetes, hypertension, prediabetes). Highly comparable GTM motion (B2B health plan and employer sales, outcomes-based contracts) and connected device/coaching service model, though its conditions of focus differ from Zerigo's dermatology scope.
• Photocil (IncellDx): Emerging home phototherapy solution for vitiligo, positioned as a direct-to-consumer device with app integration. Closest emerging competitor in the connected, at-home NB-UVB category, especially in the vitiligo indication where Zerigo is also cleared.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/zerigohealth
• LinkedInlinkedin.com/company/clarify-medical

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds9 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zerigo Health